Roadmap for new practitioners to navigate the multiple myeloma landscape

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Multiple myeloma (MM) is a plasma cell malignancy causing organ damage.
• Despite being incurable, MM treatments have improved survival rates.
• Treatment complexity has increased with novel therapies like monoclonal antibodies and cellular therapies.

Purpose of the Study:

• To provide a comprehensive guide for advanced practice providers on managing multiple myeloma.
• To clarify diagnosis, staging, and treatment strategies for MM.
• To assist in navigating the complexities of modern MM therapeutic approaches.

Main Methods:

• Literature review of current multiple myeloma research and treatment guidelines.
• Synthesis of information on diagnostic criteria, staging systems, and therapeutic options.
• Focus on practical considerations for advanced practice providers in clinical decision-making.

Main Results:

• Established diagnostic and staging criteria for multiple myeloma.
• Overview of historical and current treatment modalities, including immunomodulatory drugs, proteasome inhibitors, corticosteroids, monoclonal antibodies, and cellular therapies.
• Discussion of treatment sequencing and supportive care strategies.

Conclusions:

• Advanced practice providers require updated knowledge to manage evolving multiple myeloma treatment landscape.
• Effective navigation of diagnosis, staging, and therapy selection is crucial for optimizing patient outcomes.
• This review serves as a resource for evidence-based, patient-centered care in multiple myeloma.